The Irritable Bowel Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Irritable Bowel Syndrome. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued products.
GlobalData tracks 33 drugs in development for Irritable Bowel Syndrome by 30 companies/universities/institutes. The top development phase for Irritable Bowel Syndrome is phase ii with 12 drugs in that stage. The Irritable Bowel Syndrome pipeline has 33 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Irritable Bowel Syndrome pipeline products market are: RedHill Biopharma, Biomica and Tryptamine Therapeutics.
The key targets in the Irritable Bowel Syndrome pipeline products market include DNA Gyrase, Cannabinoid Receptor 2, and 5-Hydroxytryptamine Receptor 2A.
The key mechanisms of action in the Irritable Bowel Syndrome pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with two drugs in Phase II. The Irritable Bowel Syndrome pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Irritable Bowel Syndrome pipeline products market including Small Molecule, and Biologic.
Irritable Bowel Syndrome overview
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that affects the large intestine (colon). Symptoms include cramping, abdominal pain, bloating gas, diarrhea, backache, muscle pains, poor appetite, and constipation. These symptoms can be triggered by food, stress, and hormones. Risk factors include age and family history. Treatment includes anti-diarrheal, anticholinergic, antidepressant, and antibiotic medications.
For a complete picture of Irritable Bowel Syndrome’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
